Abstract:We investigate the robustness of adaptive chemotherapy schedules over repeated cycles and a wide range of tumor sizes. Using a non-stationary stochastic three-component fitness-dependent Moran process model (to track frequencies), we quantify the variance of the response to treatment associated with multidrug adaptive schedules that are designed to mitigate chemotherapeutic resistance in an idealized (well-mixed) setting. The finite cell (N tumor cells) stochastic process consists of populations of chemosensitive cells, chemoresistant cells to drug 1, and chemoresistant cells to drug 2, and the drug interactions can be synergistic, additive, or antagonistic. Tumor growth rates in this model are proportional to the average fitness of the tumor as measured by the three populations of cancer cells compared to a background microenvironment average value. An adaptive chemoschedule is determined by using the N→∞ limit of the finite-cell process (i.e., the adjusted replicator equations) which is constructed by finding closed treatment response loops (which we call evolutionary cycles) in the three component phase-space. The schedules that give rise to these cycles are designed to manage chemoresistance by avoiding competitive release of the resistant cell populations. To address the question of how these cycles perform in practice over large patient populations with tumors across a range of sizes, we consider the variances associated with the approximate stochastic cycles for finite N, repeating the idealized adaptive schedule over multiple periods. For finite cell populations, the distributions remain approximately multi-Gaussian in the principal component coordinates through the first three cycles, with variances increasing exponentially with each cycle. As the number of cycles increases, the multi-Gaussian nature of the distribution breaks down due to the fact that one of the three sub-populations typically saturates the tumor (competitive release) resulting in treatment failure. This suggests that to design an effective and repeatable adaptive chemoschedule in practice will require a highly accurate tumor model and accurate measurements of the sub-population frequencies or the errors will quickly (exponentially) degrade its effectiveness, particularly when the drug interactions are synergistic. Possible ways to extend the efficacy of the stochastic cycles in light of the computational simulations are discussed.

A stochastic framework for evaluating CAR T cell therapy efficacy and variability

Simulating the Dynamic Intra-Tumor Heterogeneity and Therapeutic Responses

Nonlinear dynamics of CAR-T cell therapy

Mathematical Modeling Insights into Improving CAR T cell Therapy for Solid Tumors: Antigen Heterogeneity and Bystander Effects

MCMC Methods for Parameter Estimation in ODE Systems for CAR-T Cell Cancer Therapy

Stochastic competitive release and adaptive chemotherapy

A Systematic Review of the Efforts and Hindrances of Modeling and Simulation of CAR T-cell Therapy

Bistability and Bifurcations of Tumor Dynamics with Immune Escape and the Chimeric Antigen Receptor T-Cell Therapy

Mathematical modeling insights into improving CAR T cell therapy for solid tumors with bystander effects

Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model

Are Adaptive Chemotherapy Schedules Robust? A Three-Strategy Stochastic Evolutionary Game Theory Model

Computational model for tumor response to adoptive cell transfer therapy

Bench‐to‐bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic‐pharmacodynamic model: A case study with anti‐BCMA CAR‐T

Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time

Parameter estimation and treatment optimization in a stochastic model for immunotherapy of cancer

CAR T cells for T-cell leukemias: Insights from mathematical models

Understanding the role of B-cells in CAR T-cell therapy in leukemia through a mathematical model

Mathematical modeling unveils the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome

Modeling CAR Response at the Single-Cell Level Using Conditional Optimal Transport

Modeling CAR T-Cell Therapy with Patient Preconditioning

Mapping CAR T-Cell Design Space Using Agent-Based Models